BioSpace News Archive

uniQure N.V. today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately.

Actinium Pharmaceuticals, Inc. today announced that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting selected Abstract 685 titled “Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia.

Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, announced a strategic partnership with uMotif, a clinical trial technology company putting the patient at the center of research.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions.

Sutro Biopharma, Inc. and Blackstone, announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront.

Cidara Therapeutics, Inc. announced it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution.

Amedisys, a leading provider of home health, hospice and high-acuity care, and Optum, a diversified health services company, have agreed to combine.

Vertex Pharmaceuticals Incorporated and Lonza announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that it will host its first R&D Day featuring multiple experts to showcase its clinical programs targeting retina diseases on Tuesday, July 11, 2023, from 10:00 AM – 12:00 PM EDT.